Women, doctors and the general public highly value a test that helps determine
if breast cancer patients will benefit from chemotherapy, says a study by a
Canada-wide research team led by University of Calgary scientists.
This was a two-part study on how women, medical oncologists and the general population
regarded gene expression profiling. The test is a form of personalized medicine
that analyzes a set of genes in tumours.
The first part of the research effort by Marshall’s team involved qualitative
studies that included focus groups, along with interviews with patients and
medical oncologists. Views were gathered on the value of — and challenges
with — gene expression profiling for making decisions about chemotherapy.
The results were released in two articles in Current Oncology in 2014,
including one on patient perceptions, followed
by a third published this year in The Oncologist on the views of physicians.
No comments:
Post a Comment